Advanced search
Publication Cover
Infection and Drug Resistance Volume 13, 2020 - Issue
Submit an article Journal homepage
109
Views
5
CrossRef citations to date
0
Altmetric
Original Research

Efficacy and Safety of Nemonoxacin in Outpatients with Community-Acquired Pneumonia

Bo Zhao1 Department of Pulmonary and Critical Care Medicine, Shengjing Hospital of China Medical University, Shenyang110004, Liaoning Province, People’s Republic of China
,
Xiaoxu Yu1 Department of Pulmonary and Critical Care Medicine, Shengjing Hospital of China Medical University, Shenyang110004, Liaoning Province, People’s Republic of ChinaORCID Iconhttps://orcid.org/0000-0002-6247-2172
ORCID Icon,
Rui Chen1 Department of Pulmonary and Critical Care Medicine, Shengjing Hospital of China Medical University, Shenyang110004, Liaoning Province, People’s Republic of China
&
Rui Zheng1 Department of Pulmonary and Critical Care Medicine, Shengjing Hospital of China Medical University, Shenyang110004, Liaoning Province, People’s Republic of ChinaCorrespondence[email protected]
Pages 2099-2104 | Published online: 02 Jul 2020

References

  • WHO. The top 10 causes of death[EB/OL]. Available from: https://www.who.int/en/news-room/fact-sheets/detail/the-top-10-causes-of-death. Accessed 623, 2020.
  • Welte T, Kohnlein T. Global and local epidemiology of community-acquired pneumonia: the experience of the CAPNETZ network. Semin Respir Crit Care Med. 2009;30(2):127–135. doi:10.1055/s-0029-120294119296412
  • Society CT. Guidelines for the diagnosis and treatment of community-acquired pneumonia in adults in China. Zhonghua Jiehe He Huxi Zazhi. 2016;39(4):253–279.
  • Liu YF, Gao Y, Chen MF, et al. Etiological analysis and predictive diagnostic model building of community-acquired pneumonia in adult outpatients in Beijing, China. BMC Infect Dis. 2013;13:309. doi:10.1186/1471-2334-13-30923834931
  • Kaya S, Telci CO, Oguz A. Community-acquired pneumonia requiring hospitalization. N Engl J Med. 2015;373(24):2381.
  • Adam HJ, Laing NM, King CR, et al. In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2440 clinical isolates. Antimicrob Agents Chemother. 2009;53(11):4915–4920. doi:10.1128/AAC.00078-0919738018
  • Lauderdale TL, Shiau YR, Lai JF, et al. Comparative in vitro activities of nemonoxacin (TG-873870), a novel nonfluorinated quinolone, and other quinolones against clinical isolates. Antimicrob Agents Chemother. 2010;54(3):1338–1342. doi:10.1128/AAC.01197-0920065058
  • Torres A, Chalmers JD, Dela CC, et al. Challenges in severe community-acquired pneumonia: a point-of-view review. Intensive Care Med. 2019;45(2):159–171. doi:10.1007/s00134-019-05519-y30706119
  • Sun HSH. Research progress on direct injury of Mycoplasma pneumoniae and its immunological mechanism. Zhonghua Weishengwuxue He Mianyixue Zazhi. 2015;35(1):65–68.
  • Eljaaly K, Alshehri S, Aljabri A, et al. Clinical failure with and without empiric atypical bacteria coverage in hospitalized adults with community-acquired pneumonia: a systematic review and meta-analysis. BMC Infect Dis. 2017;17(1):385. doi:10.1186/s12879-017-2495-528576117
  • Kocsis B, Domokos J, Szabo D. Chemical structure and pharmacokinetics of novel quinolone agents represented by avarofloxacin, delafloxacin, finafloxacin, zabofloxacin and nemonoxacin. Ann Clin Microbiol Antimicrob. 2016;15(1):34. doi:10.1186/s12941-016-0150-427215369
  • Eljaaly K, Alkhalaf A, Alhifany AA, et al. Photosensitivity induced by lomefloxacin versus other fluoroquinolones: A meta-analysis. J Infect Chemother. 2020;26(6):535–539. doi:10.1016/j.jiac.2020.01.00532081646
  • Lin YC, Huang YT, Tsai PJ, et al. Antimicrobial susceptibilities and molecular epidemiology of clinical isolates of Clostridium difficile in taiwan. Antimicrob Agents Chemother. 2011;55(4):1701–1705. doi:10.1128/AAC.01440-1021263053
  • Qin X, Huang H. Review of nemonoxacin with special focus on clinical development. Drug Des Devel Ther. 2014;8:765–774. doi:10.2147/DDDT.S63581
  • Roychoudhury S, Makin K, Twinem T, et al. In vitro resistance development to nemonoxacin in Streptococcus pneumoniae: a unique profile for a novel nonfluorinated Quinolone. Microb Drug Resist. 2016;22(7):578–584. doi:10.1089/mdr.2016.002127267788
  • Gajdacs M. The concept of an ideal antibiotic: implications for drug design. Molecules. 2019;24(5):892. doi:10.3390/molecules24050892
  • van Rensburg DJ, Perng RP, Mitha IH, et al. Efficacy and safety of nemonoxacin versus levofloxacin for community-acquired pneumonia. Antimicrob Agents Chemother. 2010;54(10):4098–4106. doi:10.1128/AAC.00295-1020660689
  • Guo B, Wu X, Zhang Y, et al. Safety and clinical pharmacokinetics of nemonoxacin, a novel non-fluorinated quinolone, in healthy Chinese volunteers following single and multiple oral doses. Clin Drug Investig. 2012;32(7):475–486. doi:10.2165/11632780-000000000-00000
  • Lai CC, Lee KY, Lin SW, et al. Nemonoxacin (TG-873870) for treatment of community-acquired pneumonia. Expert Rev Anti Infect Ther. 2014;12(4):401–417. doi:10.1586/14787210.2014.89488124579813
  • Tan CK, Lai CC, Liao CH, et al. Comparative in vitro activities of the new quinolone nemonoxacin (TG-873870), gemifloxacin and other quinolones against clinical isolates of Mycobacterium tuberculosis. J Antimicrob Chemother. 2009;64(2):428–429. doi:10.1093/jac/dkp17419454523
  • Dooley KE, Golub J, Goes FS, et al. Empiric treatment of community-acquired pneumonia with fluoroquinolones, and delays in the treatment of tuberculosis. Clin Infect Dis. 2002;34(12):1607–1612. doi:10.1086/34061812032896

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.